A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs Lunsekimig (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Sanofi
- 12 Nov 2024 New trial record